Envista Holdings Corp (NVST) - Stock Analysis
Last updated: Jun 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Envista presents strong Q4 2025 beats, positive analyst upgrades, a raised full-year guidance, robust institutional buying, and a ~24% price gain with breakout above 21-day SMA, supported by product momentum in implants and imaging, though tariff and macro risks temper short-term certainty.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Stability ⢠Cash Flow Pressure ⢠Intangible Heavy NVST shows stable 55% gross margins and solid liquidity, but thin net profitability, weak near-term cash flow, a heavy intangible asset base, and a rich valuation limit the appeal.
Price Behavior
Key Price Behavior Insights: ⢠Failed rallies ⢠Support holding ⢠Momentum repair Support Level: $22.40 to $22.90 Resistance Level: $23.55 to $23.77 NVST trended lower last month, with repeated failures near $23.55-$23.77 and a dip to $22.40, but the rebound to $23.10 keeps $22.40-$22.90 support in focus until price reclaims resistance.
Sentiment & News
Key News Insights: ⢠Margin expansion ⢠Growth momentum ⢠Valuation upside Envista's recent headlines point to improving growth, margin expansion, and a still-attractive valuation, though investors are watching to see if the latest operating gains can continue.
AI Summary
NVST now looks like a repair story rather than a broken one, but with valuation already pricing in recovery, the key test is whether the next few quarters deliver sustained positive operating cash flow and margin gains strong enough to break the $23.55-$23.77 resistance band; if not, the stock offers limited room for disappointment.
Description
Envista Holdings Corp., headquartered in Brea, California, manufactures and sells a broad range of dental products and tools and employs about 12,800 full-time staff. The company operates two reporting segments: Specialty Products & Technologies, which supplies dental implant and prosthetic systems, orthodontic products and related treatment software; and Equipment & Consumables, which provides dental office equipment, imaging and visualization systems, restorative and endodontic materials, and infection-prevention supplies. Its offerings support diagnosis, treatment and routine clinical procedures across general and specialty dental practices.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 10 | Feb 17 | NVST | Envista Holdings Corp | Envista presents strong Q4 2025 beats, positive analyst upgrades, a raised full-year guidance, robust institutional buying, and a ~24% price gain with breakout above 21-day SMA, supported by product momentum in implants and imaging, though tariff and macro risks temper short-term certainty. | Closed | -7.0% |